| Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis PA Olivera, JS Lasa, S Bonovas, S Danese, L Peyrin-Biroulet Gastroenterology 158 (6), 1554-1573. e12, 2020 | 279 | 2020 |
| Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis JS Lasa, PA Olivera, S Danese, L Peyrin-Biroulet The Lancet Gastroenterology & Hepatology 7 (2), 161-170, 2022 | 276 | 2022 |
| Next generation of small molecules in inflammatory bowel disease P Olivera, S Danese, L Peyrin-Biroulet Gut 66 (2), 199-209, 2017 | 217 | 2017 |
| Big data in IBD: a look into the future P Olivera, S Danese, N Jay, G Natoli, L Peyrin-Biroulet Nature Reviews Gastroenterology & Hepatology 16 (5), 312-321, 2019 | 149 | 2019 |
| International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease PA Olivera, S Zuily, PG Kotze, V Regnault, S Al Awadhi, P Bossuyt, ... Nature Reviews Gastroenterology & Hepatology 18 (12), 857-873, 2021 | 117 | 2021 |
| JAK inhibition in inflammatory bowel disease P Olivera, S Danese, L Peyrin-Biroulet Expert review of clinical immunology 13 (7), 693-703, 2017 | 100 | 2017 |
| Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review L Martelli, P Olivera, X Roblin, A Attar, L Peyrin-Biroulet Journal of gastroenterology 52, 19-25, 2017 | 92 | 2017 |
| Surgical rates in the era of biological therapy: up, down or unchanged? P Olivera, A Spinelli, C Gower-Rousseau, S Danese, L Peyrin-Biroulet Current opinion in gastroenterology 33 (4), 246-253, 2017 | 78 | 2017 |
| International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases F d'Amico, DT Rubin, PG Kotze, F Magro, B Siegmund, T Kobayashi, ... UEG Journal 9 (4), 451-460, 2021 | 73 | 2021 |
| moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis PB Allen, P Olivera, P Emery, D Moulin, JY Jouzeau, P Netter, S Danese, ... Alimentary Pharmacology & Therapeutics 45 (8), 1058-1072, 2017 | 53 | 2017 |
| Treatment persistence for infliximab versus adalimumab in Crohn's disease: a 14-year single-center experience P Olivera, L Thiriet, A Luc, C Baumann, S Danese, L Peyrin-Biroulet Inflammatory Bowel Diseases 23 (6), 976-985, 2017 | 45 | 2017 |
| Effectiveness of golimumab in ulcerative colitis: a review of the real world evidence P Olivera, S Danese, L Pouillon, S Bonovas, L Peyrin-Biroulet Digestive and Liver Disease 51 (3), 327-334, 2019 | 29 | 2019 |
| Safety of S1P modulators in patients with immune-mediated diseases: a systematic review and meta-analysis JS Lasa, PA Olivera, S Bonovas, S Danese, L Peyrin-Biroulet Drug Safety 44, 645-660, 2021 | 25 | 2021 |
| Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs PA Olivera, JS Lasa, G Peretto, S Zuily, S Danese, L Peyrin‐Biroulet Alimentary Pharmacology & Therapeutics 57 (11), 1231-1248, 2023 | 20 | 2023 |
| Treatment adherence in inflammatory bowel disease patients from Argentina: a multicenter study J Lasa, G Correa, C Fuxman, L Garbi, ME Linares, P Lubrano, A Rausch, ... Gastroenterology research and practice 2020 (1), 4060648, 2020 | 19 | 2020 |
| Biobetters in patients with immune-mediated inflammatory disorders: an international Delphi consensus F d'Amico, V Solitano, D Aletaha, A Hart, F Magro, C Selmi, SC Ng, ... Autoimmunity Reviews 20 (7), 102849, 2021 | 18 | 2021 |
| Small intestinal bacterial overgrowth prevalence in celiac disease patients is similar in healthy subjects and lower in irritable bowel syndrome patients JS Lasa, I Zubiaurre, I Fanjul, P Olivera, L Soifer Revista de Gastroenterología de México (English Edition) 80 (2), 171-174, 2015 | 18 | 2015 |
| Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America D Balderramo, AB Quaresma, PA Olivera, MC Savio, MPG Villamil, ... The Lancet Gastroenterology & Hepatology 9 (3), 263-272, 2024 | 16 | 2024 |
| Physicians’ perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease … P Olivera, WJ Sandborn, J Panés, C Baumann, G D'Haens, S Vermeire, ... Alimentary pharmacology & therapeutics 47 (6), 773-783, 2018 | 12 | 2018 |
| Practical management of biosimilar use in inflammatory bowel disease (ibd): a global survey and an international delphi consensus F D’Amico, V Solitano, F Magro, PA Olivera, J Halfvarson, D Rubin, ... Journal of Clinical Medicine 12 (19), 6350, 2023 | 10 | 2023 |
Silvio DaneseOspedale San RaffaeleAdresse e-mail validée de hsr.it